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Background: The accumulation of the misfolded forms of cellular prion protein, i.e. prions (PrPSc), in the brain is
one of the crucial characteristics of fatal neurodegenerative disorders, called transmissible spongiform
encephalopathies (TSEs). Cellular prion protein is normally linked to the cell surface by the
glycosylphosphatidylinositol (GPI) anchor. There is accumulating evidence that the GPI-anchorless prion protein may
act as an accelerator of formation and propagation of prions. In the TSE affected human brain we have previously
discovered a novel GPI-anchorless prion protein fragment, named PrP226*, which ends with the tyrosine 226. This
fragment can be labeled specifically by the monoclonal antibody V5B2.
Methods: We developed a DELFIA based assay for quick and sensitive detection of the PrP226* fragment in human
brain tissue homogenates. By calculating the ratio between the signals of native (N) and denatured (D) samples
applied to the assay we were able to observe significant difference between 24 TSE affected brains and 10 control
brains. The presence of PrP226* in brain tissue was confirmed by western blot.
Results: Our results demonstrate that PrP226* is present in small quantities in healthy human brain, whereas in
degenerated brain it accumulates in prion aggregates, proportionally to PrPSc. Samples with high D/N ratio
generally comprised more proteinase K resistant PrP, while no correlation was found between the quantity of
PrP226* and standard classification of Creutzfeldt-Jakob disease (CJD).
Conclusions: In the present study we show that the PrP226* fragment accumulates in prion aggregates and after
being released from them by a denaturation procedure, could serve as a proteinase K digestion independent
biomarker for human TSEs. The PrP226* assay described in this paper offers a tool to follow and study this unique
anchorless PrP fragment in various parts of human brain and possibly also in other tissues and body fluids.
Keywords: Transmissible spongiform encephalopathies, Creutzfeldt-Jakob disease, GSS, Prion, V5B2, Immunoassay,
DELFIA, Anchorless PrP, PrP fragment, Proteinase KBackground
Transmissible spongiform encephalopathies (TSEs), or
prion diseases, are phenotypically heterogeneous group of
fatal neurodegenerative disorders of humans and animals.
Human prion diseases include Creutzfeldt-Jakob disease
(CJD), kuru, Gerstmann-Sträussler-Scheinker disease
(GSS) and Fatal familial insomnia. Prion diseases can be
sporadic (i.e. spontaneous, 85%), familial (i.e. inherited,
10-15%) or acquired (i.e. transmitted by infection, 2-3%).* Correspondence: vladka.curin@ztm.si
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distribution, and reproduction in any mediumPrion diseases are characterized by misfolding of the
normal cellular prion protein (PrPC) into the pathological
isoform (PrPSc) [1]. Conversion into abnormal PrPSc is as-
sociated with an increase in β-sheet secondary structure
and aggregation of the protein [2,3]. As a result, PrPSc is
insoluble in non-denaturing detergents and partially re-
sistant to protease digestion. Diagnostic methods are
mostly based on the treatment of samples with proteinase
K (PK) which degrades PrPC, while the resistant fragment
of pathological prion protein (PrPres) can be detected with
anti-PrP antibodies.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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focused mainly on differences in the PrPres size and gly-
cosylation site occupancy in conjunction with the pres-
ence of mutations and polymorphisms in the prion
protein gene (PRNP). Based on differences in gel mobil-
ity and N-terminal sequence of the core fragments
(PrP27–30) generated by PK digestion, Parchi et al.
originally identified two major human PrPSc types in hu-
man prion diseases: type 1 having a relative molecular
mass 21 kDa of nonglycosylated PrPres with the primary
cleavage site at residue 82 and type 2 having a relative
molecular mass 19 kDa with the primary cleavage site at
residue 97 [4,5]. The two PrPSc types in conjunction
with PRNP gene polymorphism at codon 129, that en-
codes either methionine (Met) or valine (Val), provided
for the first time a molecular basis for disease classifica-
tion [6]. An alternative classification has been suggested
by Collinge et al. [7,8]. In GSS, two different pathological
phenotypes are associated either with type 1 PrPres or
with a 7-kDa to 8-kDa PrPres fragment [9].
As the research in the field of prion biology advanced,
the evidence of the physicochemical heterogeneity of
PrPSc in human and animal prion diseases accumulated
[9-13]. The classical typing thus became insufficient for
understanding the complex coexistence of distinct struc-
tural conformers of PrPSc in prion diseases formation
and progression.
The reports on various truncated forms of the abnor-
mal protein are also in accordance with the structural
diversity of the PrPSc. One of the identified PrP frag-
ments is the glycosylphosphatidylinositol (GPI)-anchor-
less PrP, truncated at the very C terminus [13-15].
Although the role of the GPI anchor in PrPSc replication
and disease propagation remains unclear [16-18], there
is increasing evidence on GPI-anchorless PrP, i.e. PrP
(ΔGPI), acting as an accelerator of formation and propa-
gation of prions. Heterozygous transgenic mice lacking
the sequence for GPI-anchor on one of the PrP alleles,
developed clinical signs and died faster than the wild-
type mice upon the TSE infection, while their brains
appeared to have PrPres generated from both, GPI-
anchored and anchorless PrP forms [19]. Stöhr et al.
reported recently that mice overexpressing PrPΔGPI de-
veloped a spontaneous neurological disease [20]. A simi-
lar situation was described in human patients with stop
codon mutations at the codons 226 and 227, resulting in
the formation of C-terminally truncated PrP, ending
either with tyrosine 225 or with tyrosine 226, respect-
ively. Both patients were heterozygous, with the second
allele coding for normal PrP, and displayed atypical prion
protein amyloidoses [21]. GPI-anchorless PrP was also
found on blood cells of patients with paroxysmal noctur-
nal hemoglobinuria suffering from the clonal defect in
GPI synthesis [22,23]. However, in their affected cellsthe protein seems to be expressed intracellularly, likely
in a transmembrane form [23] and patients do not ex-
hibit neurological symptoms.
We previously described development and characteris-
tics of the monoclonal antibody V5B2, raised against hu-
man PrP peptide 214–226 [24]. V5B2 specifically
recognizes C-terminally truncated fragment of the prion
protein that ends with the residue Y226, which was
named PrP226* [25]. V5B2 thus represents a unique tool
to study localization and behavior of this GPI-anchorless
PrP fragment in different biological samples. In this
study we developed a V5B2 based sandwich DELFIA
immunoassay for detection of the fragment PrP226* in
human brain homogenates. Our method is based on
comparison of the quantity of PrP226*, measured in na-
tive and denatured samples. Its principle is similar to the
Conformation-Dependent Immunoassay, reported by
Safar et al. [26]. We tested 20 sCJD, 3 fCJD, 1 GSS and
10 non-CJD brain homogenates and we found that the
fragment PrP226* accumulates in TSE affected brain,
most abundantly in the GSS case. The amount of
PrP226* was generally proportional to the amount of
PrPSc and PrPres in prion aggregates.
Results
PrP226* C-terminus is degraded by PK
Western blot analyses of sCJD and non-CJD brain ho-
mogenates were performed with two anti-PrP mAbs,
6H4, that reacts with the epitope PrP144-152 and V5B2,
that reacts with the epitope PrP214-226, with last three
amino acids AYY being crucial for binding (Figure 1A).
It has been shown before that AYY must be freely ex-
posed; a single amino acid addition to the C-terminus of
this epitope completely abolishes V5B2 binding. There-
fore V5B2 is specific for the PrP fragment that ends with
226, i.e. PrP226* [25]. PrP226* is barely visible in non-
CJD brain, but is present in substantial amounts in hu-
man sCJD brain homogenates in all three glycoforms. In
contrast, signals of similar intensity were obtained for
both sCJD and non-CJD samples when using 6H4 for
the immunodetection. PrP226* migrates a few kDa
faster than the whole PrP (Figure 1B). PK digestion of
samples resulted in PrPres, detected with mAb 6H4,
while the V5B2 epitope on PrP226* was largely de-
graded (Figure 1C).
Optimization of denaturation conditions for the
immunoassay
We have previously detected PrP226* in PrPSc deposits
in the brain of sCJD patients by immunohistochemistry
(IHC) [24]. Therefore, in order to be able to detect the
PrP226*, packed in prion aggregates, we set a denatur-
ation protocol for brain homogenates. We first opti-
mized denaturation of samples by Gdn-SCN in a V5B2/
Figure 1 Western analysis of human brain homogenates. (A) Epitopes of mAbs 6H4 and V5B2, which were used for immunodetection.
(B) Analysis of six sCJD and two non-CJD brain homogenates without PK treatment. (C) The effect of PK digestion on the immunodetection with
mAbs 6H4 and V5B2.
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were treated with increasing concentration of Gdn-SCN
at 60°C for 15 min (Figure 2A). When the concentration
of Gdn-SCN, to which the samples were exposed, was
higher than 1 M, we noticed a substantial decrease of
the signal, which could be at least partially attributed to
the denaturation of the capturing antibody and thusFigure 2 Determination of the optimal Gdn-SCN concentration for de
(■ and ●) were treated with increasing concentration of Gdn-SCN (0-3 M).
measured by V5B2/EM20-b sandwich ELISA. (B) The effect of Gdn-SCN on t
was first mixed with 3 M Gdn-SCN 1:1 (v/v), than diluted 5x and further ser
denatured recombinant PrP226* (●) and PBS (▲).reducing its binding capacity (Figure 2A). In order to
study this effect of Gdn-SCN, we mixed recombinant
PrP226* (recPrP226*, at the concentration 10 μg/ml)
with 3 M Gdn-SCN, volume ratio 1:1. The mixture was
then serially diluted and loaded to the wells of the mi-
crotiter plate. The highest signal was obtained at the
concentration of 0.075 M Gdn-SCN (Figure 2B). Innaturation of samples. (A) Two 10% sCJD brain homogenates
Samples were 10 times diluted and the fragment PrP226* was
he capturing antibody V5B2 was determined using rec PrP226* which
ially diluted prior to loading on a plate (■). Controls were titrated non-
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10% brain homogenates (vol 1:1). Samples were incu-
bated for 15 min at 60°C and then further diluted 20× to
a final concentration of 0.25% brain homogenate in
0.075 M Gdn-SCN.
PrP226* assay
The determined denaturing and non-denaturing con-
ditions were used to measure the signal of PrP226* inFigure 3 Analyzes of brain homogenate samples with PrP226* assay.
brain homogenates (B, D, F) were analyzed with V5B2/EM20-b DELFIA und
15 min at 60°C (C, D). Absolute values are represented as counts per minu
represented in (E) and (F). Error bars were calculated from two independen
samples are presented without error bars, as an example only, as they diffe
of DELFIA to slight variations in the protocol.23 CJD, 1 GSS and 10 non-CJD brain homogenates by
sandwich DELFIA. In CJD/GSS samples, the signal at
denaturing conditions was usually higher than in non-
denaturing conditions (Figure 3A and C), whereas in non-
CJD samples, the signal decreased after denaturation
(Figure 3B and D). Although this phenomenon was al-
ways observed, the measurements of the same samples
differed significantly between experiments, due to the
sensitivity of DELFIA to slight variations in the23 CJD and one GSS brain homogenate (A, C, E) and 10 non-CJD
er native conditions (A, B) or after denaturation with 3 M Gdn-SCN for
te (cpm), measured by time-resolved fluorescence. The D/N ratio is
t experiments (E). Absolute measurements of native and denatured
red significantly between repeated experiments, due to the sensitivity
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CJD as well as the repeatability of the assay was signifi-
cantly improved after applying the ratio between the
signal of denatured samples and the signal of native
samples (D/N, [26]). D/N values of all 10 non-CJD
samples were ≤ 0.65 (Figure 3F). CJD/GSS samples
formed two groups, the first with D/N ratios between
0.55 and 1.58 (samples 3, 8, 15, 16, 18, 19 and 24), and
the second with D/N ratios ≥ 2.0 (all other CJD/GSS
samples, Figure 3E).
To investigate whether the low D/N values of the first
group of CJD/GSS samples were caused by insufficient
homogenization or denaturation of the samples, we re-
peated the measurements of these samples after add-
itional homogenization by passage through the insulin
syringe with 31G needle and by their denaturation at
higher temperature (ie. by 1.5 M Gdn-SCN for 10 min at
90°C). However, the treatment did not lead to the
change of D/N values of these samples (data not shown).
We proved that D/N correlates with D values alone, i.e.
with the concentration of PrP226*, detected after the de-
naturation of samples (Additional file 1).
Stability of the fragment PrP226* in human brain
homogenates
The stability of PrP226* fragment was determined by
V5B2/EM20-b ELISA in the immediately frozen aliquot
and the duplicate left overnight at RT. We observed that
in average 94.3% (±SD 14.1%) of PrP226* remained in
non-CJD and 99.2% (±SD 16.9%) of PrP226* in sCJD
brain homogenates (Figure 4A). Additional experiment
was performed by spiking recombinant PrP226* into the
non-CJD brain homogenate, which was stored at 4°C, at
RT or at 37°C. Aliquots, taken at three time points, were
examined by western blot. The densitometry analyses
showed that, compared to the control recPrP226*Figure 4 Stability of the PrP226* fragment in brain homogenates. (A)
split into 2 aliquots, one of each was left at RT overnight and the other wa
by V5B2/EM20-b sandwich ELISA. Absorbance values of two non-CJD samp
considered. The percentage of the PrP226* signal measured in samples left
(B) Recombinant human PrP226* (recPrP226*) was spiked into a non-CJD b
RT (lines 4–6) or at 37°C (lines 7–9). RecPrP226* was added as a control (lin(Figure 4B, line 10), the spiked recPrP226* was degraded
for 25% at the most, in the aliquot that was left for two
hours at RT (Figure 4B).
Correlation of PrP226* assay with CDI
The results from PrP226* assay were compared to CDI,
applied to similar denaturation conditions as were used
for the PrP226* assay, with the sole exception that guan-
idine hydrochloride (Gdn-HCl) was used instead of
Gdn-SCN. CDI assay, described by Safar et al. [26], de-
pends on the effect of increasing concentrations of Gdn-
HCl to unmask epitopes in PrPSc that become hidden
during the structural rearrangements involved in the for-
mation of PrPSc and its deposits. In our setting, samples
exposed to 4 M Gdn-HCl were detected in a FH11/3F4-b
sandwich DELFIA and D/N values were obtained for all
CJD/GSS samples (except the sample 20, which was no
more available, Figure 5A) and all of the non-CJD samples
(not shown). The cut-off D/N value between CJD/GSS
and non-CJD measured with CDI was determined to be
1.0. The statistical correlation between the D/N values of
CJD/GSS samples measured by V5B2/EM20-b DELFIA
and the D/N values of the same samples, measured by
CDI by FH11/3F4-b DELFIA (Figure 5B), proved to be
highly significant (P value 0.0005 and Pearson correlation
factor r = 0.6673) when evaluating all 23 values. These
data indicate that the amount of PrP226* in CJD/GSS
brain homogenates is proportional to the total amount of
misfolded PrPSc in them.
PrP226* correlation with PrPres
Next we evaluated the correlation between the PrP226*
D/N values and the PK resistance of samples. For this
purpose we chose 12 out of 24 CJD/GSS samples which
were outstanding due to their very low or very high D/N
ratio. Western blot analyses performed with mAb 3F410% brain homogenates from 6 non-CJD and 6 sCJD patients were
s refrozen immediately. Samples were measured on the following day
les were not higher than the background and were therefore not
at RT is calculated relatively to the signal of frozen samples.
rain homogenate and left for 30 min, 1 h or 2 h at 4°C (lines 1–3), at
e 10). V5B2 (5 μg/ml) was used as detecting antibody.
Figure 5 CDI and PK resistance of PrPSc in CJD samples and the correlation with the PrP226*assay. (A) 23 out of 24 CJD/GSS brain
homogenates were analyzed with FH11/3F4-b DELFIA and D/N ratios were calculated. (B) Correlation diagram between D/N ratio in PrP226*
assay and D/N ratio in CDI. (C) 12 out of 24 CJD/GSS brain homogenates were digested with 50 μg/ml PK. Western blots were developed with
3F4, density of bands was evaluated and expressed as a percentage of the resistant PrP compared to the non-digested PrP. (D) Correlation
diagram between D/N ratio in PrP226* assay and PK resistance.
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30 min) led to substantial digestion of PrP in the majority
of samples, however significant differences in the PrPres
amount were detected between the individual samples.
Values expressed as percentage of the PrPres signal as to
the PrP signal in untreated samples, varied from 0-60%
(Figure 5C). When PrP226* D/N ratio was compared to
the percentage of PrPres in CJD/GSS samples, we found a
correlation for all 12 values (P value 0.0036 and Pearson
correlation factor r = 0.7438; Figure 5D). These data indi-
cate that samples with higher PrP226* D/N ratios are in
general also more PK resistant.
PrP226* correlation with standard CJD classifications
To see whether the proportion of PrP226* in deposits
(i.e. the D/N ratio in PrP226* assay) correlates with
standard CJD sample classifications, D/N ratio mea-
sured by PrP226* assay was compared to the PrPSc type,
to the Met/Val polymorphism at the codon 129, to the
presence or absence of 14-3-3 protein in the cerebro-
spinal fluid (CSF) and to the PrPSc deposition pattern,
determined by the immunohistochemical evaluation ofCJD/GSS samples. Our results demonstrate that the D/N
ratio in PrP226* assay correlates neither with PrPSc
types nor with Met/Val polymorphism at the codon 129
(Figure 6A and B, respectively). We also found no cor-
relation between D/N ratio and the presence of 14-3-3
protein in the CSF (Figure 6C). Finally, IHC was
performed on frontal cortex sections of nine chosen
samples (samples 1, 4, 5, 8, 15, 16, 19, 22 and 24). The
presence of plaques, as well as the morphology of depo-
sitions was evaluated but did not correlate with the D/N
ratio in PrP226* assay (Figure 6D). For more information
on samples, see Additional file 2.Discussion
In the present study, we developed a sandwich immuno-
assay for detecting glycosylphosphatidylinositol (GPI)
anchorless PrP fragment ending with amino acid Y226,
PrP226* [25]. The method is based on the use of mono-
clonal antibody V5B2 [24] and enables identification of
the PrP226* fragment which is differently accessible in
CJD and non-CJD brain tissue (Figure 1B).
Figure 6 Correlation of D/N ratio in PrP226* assay with standard CJD classifications. The D/N ratio measured in V5B2/EM20-b DELFIA was
compared (A) to the PrPSc type, (B) to the methionine (M)-valine (V) polymorphism at the codon 129, (C) to the presence or absence of the 14-3-3
protein found in CSF and (D) to PrPSc deposition type evaluated by immunohistochemistry with 6H4 after PK cleavage of 9 CJD/GSS samples of frontal
cortex. The intensity of prion plaques, patchy/perivacuolar depositions and diffuse/synaptic depositions were evaluated at the scale 0 to 3. In all
samples more than one deposition type was found. See also Additional file 2.
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PrP226* in a brain homogenate, i.e. the signal mea-
sured in a denatured sample, divided by the signal
measured in the same sample under native conditions.
Gdn-SCN-induced denaturation releases previously
unavailable PrP226* from prion aggregates, therefore
unmasking new V5B2 epitopes. The approach in
PrP226* assay is based on similar principles as the
Conformation-Dependent Immunoassay [26] and is
exploiting chaotropic salts to unmask epitopes buried
in prion aggregates. Chaotropic agents like Gdn-SCN,
Gdn-HCl or urea disrupt hydrogen bonds responsible
for the secondary structure (α-helices and β-sheets) of
proteins. Since hydrogen bonding also helps to main-
tain tertiary and quaternary structures of proteins, de-
naturation of human brain homogenates induced with
Gdn-SCN (or Gdn-HCl), leads to dissociation of prion
aggregates as well as to uncoiling of the PrP polypep-
tide chain.
Different brain tissue samples might need different de-
naturation conditions for the optimal dissociation of
prion aggregates (Figure 2A). However 1.5 M Gdn-SCN
was chosen for the PrP226* assay as a compromise to
ensure the efficient denaturation of most of the samples.We further optimized the dilution of samples after de-
naturation to assure that the final concentration of Gdn-
SCN present on the microtiter plate affected minimally
the binding capacity of V5B2 (Figure 2B). When recom-
binant PrP226* was used in the assay instead of brain
homogenates, a 20% decrease of the signal was observed
even when dilution of Gdn-SCN reached 0.075 M. The
signal was further dropping rapidly upon the application
of denaturant at final concentrations higher than 0.1 M,
despite applying higher concentrations of recombinant
PrP226* at the same time. The reason for the observed
signal decrease could be the structural change of a part
of V5B2 paratopes and its epitopes when exposed to
denaturant.
The PrP226* assay takes advantage of the monoclonal
antibody V5B2, directed against C-terminally truncated
fragment of human prion protein that ends with the
residue Y226. V5B2 is highly specific for all prion pro-
tein fragments ending with the AYY motif. Namely,
deprivation of a single tyrosine as well as addition of a
single amino acid to tyrosine 226, would completely dis-
rupt the V5B2 binding thus proving that the structure of
the epitope at the PrP226* terminus is significantly differ-
ent from the structure of the corresponding C-terminal
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PrP [25]. These findings correspond very well to recent
report of Jansen et al. on two patients with stop codon
mutations in one allele of the PRNP gene, resulting in
expression of either PrP225 or PrP226 (i.e. PrP226*,
[25]), apart from the normal, GPI-linked PrP. The two
patients had strikingly different disease phenotypes,
showing that the difference in the exposition of the
tyrosine 226 may significantly affect the site of amyloid
deposition and the overall phenotype of the prion dis-
ease [21].
The PrP226* assay was evaluated using 23 CJD, 1 GSS
and 10 non-CJD human brain homogenates. We found
that D/N values of PrP226* are lower than 0.7 for non-
CJD brain and higher than 1.0 for 80% of CJD/GSS pa-
tients’ brain (Figure 3). Moreover, we showed that
PrP226* is relatively stable, meaning that only a minor
part of it could be ascribed to the post-mortem or post–
homogenization process of degradation by the released
brain proteases (Figure 4A and B). Most of the PrP226*
fragment is therefore present in the brain already at the
time of death. Our study thus demonstrates that
PrP226* accumulates in the prion protein deposits dur-
ing the course of disease and could therefore serve as a
biomarker for human TSEs.
We had the opportunity to also include a GSS sample
in our study. This unusual GSS case was caused by a
classical P102L mutation, but the manifestation of the
disease resembled CJD [27]. The PrP226* assay showed
a fivefold higher reaction for the denatured GSS sample,
compared to the average signal of other brain homoge-
nates tested (Figure 3C, sample 22), showing a greater
abundance of the PrP226* fragment in GSS brain. Inter-
estingly, Jansen et al. also described a GSS-like disease
phenotype in a patient expressing PrP226* fragment due
to a stop codon mutation on one PRNP allele [21].
To further elucidate the reason for D/N ratio differences
among the samples, included in our study, we measured
the PK resistant fraction of PrP (PrPres) in the samples
with either very high or very low D/N (Figure 5C). We
found a general correlation between the proportion of
PrP226* and PrPres in prion aggregates. However, it is
worth stressing that we were able to clearly identify as
positive one of the two CJD samples, which were com-
pletely degraded by 50 μg/ml PK (Figure 5D, sample 1).
D/N values obtained with the PrP226* assay, correlate
with D/N values measured by CDI assay, which impli-
cates that the amount of PrP226* in aggregates is pro-
portional to the amount of total misfolded PrP present
in them (Figure 5A and B).
Fragments that might be related to the truncated PrP,
PrP226*, have already been described in animal and hu-
man TSE affected brain. Stahl et al. showed that 15% of
PrPSc extracted from hamster brain was found toterminate at glycine 228 [14]. Although the site of
cleavage of this fragment is different from that of
PrP226*, the two fragments might originate from the
same mechanism, but differ due to different amino acid
sequence between hamster (mouse) and human PrP in
the region of protease cleavage site. It is less likely that
PrP226* originates in further proteolysis of the PrP228,
as PrP226* has never been detected in mice (unpub-
lished data).
Notari et al. identified two GPI-anchorless fragments
in human CJD brain that migrate 2–3 kDa faster than
PrPres (or PrP27–30) [13]. The fragments, which lack a
few amino acids together with the GPI anchor at the
very end of the C terminus, have an apparent molecular
mass of about 18.5 kDa when associated with PrP27–30
type 1 and of 17 kDa when associated with type 2.
Notari et al. also identified a significant heterogeneity in
the amount of these fragments among the tested CJD
subtypes [13]. When we compared the D/N ratio of
PrP226*, measured in 24 CJD/GSS samples, to western
blot profiles, to Met/Val polymorphism at the codon
129, to the presence of 14-3-3 protein in CSF or to the
type of PrPSc depositions, we did not find a correlation
with any of the mentioned parameters.
In the present study, we also demonstrated that
PrP226* can be detected in the brain of some of the pa-
tients having no neurological disorders (Figure 3B). It is
known that although the majority of the PrPC is bound
to the cell membranes via a GPI anchor, a soluble form
of PrPC is shed in a normal metabolic process from vari-
ous cell types, e.g. neurons, splenocytes and platelets
[28-30]. Anchorless PrP, i.e. PrP(ΔGPI), has also been
identified in the medium of other cultured cells [31,32],
in human cerebrospinal fluid and in serum [28,32]. The
exact cleavage site on the PrP molecule has not been
identified in these studies. Parkin et al. showed that apart
from being removed by phospholipase C at serin 231, a
significant proportion of PrPC is shed from cell surfaces
by the proteolytic action of a zinc metalloprotease which
cleaves PrPC very close to the C terminus [15]. Whether
the anchorless PrP226* originates in action of zinc
metalloproteases and what might be its biological signifi-
cance in healthy or diseased human brain remains to be
determined.
Conclusions
The PrP226*assay is based on assessing differences be-
tween the levels of the soluble form of PrP226* and the
PrP226*, packed in prion aggregates. Using this method
we were able to show, that this anchorless PrP fragment
is a part of prion aggregates in the brain of CJD/GSS pa-
tients. We also show that PrP226* can be detected in
some non-CJD brains. The role of PrP226* in healthy
brain and the importance of its involvement in the
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However, the accumulation of PrP226* in prion deposits,
shown in this study, and its toxicity when overexpressed
[21], resembles the recent findings in mice where an-
chorless PrP was involved in PrPSc formation [19] and,
when overexpressed, also the sole cause of the disease
[20,33]. The PrP226* assay, described in this paper, offers
a tool to follow and study this anchorless PrP fragment
in various parts of human brain and possibly also in
other tissues and body fluids.
Methods
Antibodies
The following mouse monoclonal antibodies (mAbs) rec-
ognizing different epitopes in human PrP were used:
V5B2, epitope 214–226 [24]; EM20, epitope in the region
121–231 (EXBIO Praha); FH11, epitope 51–54 (TSE
resource centre, Rosslin Institute, Scottland); 3F4, epitope
109–112 (Covance); 6H4, epitope 144–152 (Prionics).
Conjugated antibodies were prepared by covalent
labeling of primary antibodies with biotin using EZ-Link®
Sulfo-NHS-LC-Biotinylation Kit (Thermo Scientific).
The dilutions of the conjugates used in the assays were
optimized in titration assays to 0.5 μg/ml for both con-
jugates, biotinylated EM20 (EM20-b) and biotinylated
3F4 (3F4-b).
Tissues
The study was carried out on freshly frozen brain tissue
samples of one GSS, 20 sCJD and 3 fCJD patients. The
study and its protocol were approved by the Central Ethics
Committee of Thomayer Hospital and the Institute for
Clinical and Experimental Medicine in Prague. In accord-
ance with the guidelines of The Declaration of Helsinki in-
formed consent was obtained either from patient or from
relatives and all data were analyzed with respect to patient
privacy.
CJD/GSS samples were previously confirmed by the
National Reference Laboratory for TSE/CJD in Czech
Republic. For negative controls we used freshly frozen
brain tissue samples of 10 non-CJD cases without neuro-
logical disorders.
PrPSc typing (according to the fragment size and
glycoform ratio) and 14-3-3 determination were performed
according to the standard procedures [34].
Preparation of brain homogenates
sCJD/GSS and non-CJD brain tissue samples were homog-
enized in 9 volumes of ice-cold lysis buffer (0.5% Sodium
deoxycholate, 0.5% Tergitol, 25 mM Tris, pH 7.6) using a
HT1000 Potter homogenizer. Brain tissue homogenates
(10%, w/v) were not centrifuged, but aliquoted and stored
at −80°C.V5B2/EM20-b sandwich ELISA
NUNC MaxiSorp microtiter plates were coated with pri-
mary antibody V5B2 (1 μg/ml) in carbonate-bicarbonate
buffer, pH 9.6 and incubated overnight at 4°C. Plates
were than washed with the washing buffer (0.05%
Tween/PBS buffer, pH 7.2) and blocked with the
blocking buffer (1% BSA in washing buffer). Prepared
native and denatured samples were further diluted 20x
in the blocking buffer to final 0.25% brain homogenates.
50 μl of samples were loaded and incubated for 90 min
at 37°C. Plates were washed and biotinylated antibody
EM20-b (0.5 μg/ml), diluted in the blocking buffer, was
added for 60 min at 37°C. After washing, avidin-HRP
was added (Pierce, 1:5000) for 30 min at 37°C. After a
final wash, TMB substrate solution (Pierce) was added.
The reaction was stopped after 20 min by addition of
0.1 M H2SO4 and the absorbance was measured at
450 nm.V5B2/EM20-b DELFIA (Dissociation-Enhanced Lanthanide
Fluorescent Immunoassay)
DELFIA was performed in the same way as sandwich
ELISA until the addition of the biotinylated mAb, with
the exception that PerkinElmer Wash Solution was used
instead of washing buffer. After this step, plates were
washed and further incubated for 30 min at 37°C with
streptavidin-Eu (PerkinElmer), diluted to 0.125 μg/ml in
Assay Buffer (PerkinElmer). After final washing, En-
hancement solution (PerkinElmer) was added. Emission
peaks were measured as time-resolved fluorescence at
613 nm from the top of the wells after excitation of the
sample at 340 nm, delay 400 μs.Stability of the PrP226* fragment
The stability of PrP226*, inherently present in the brain,
was measured in fresh brain homogenates of 6 CJD pa-
tients and 6 non-CJD individuals. Each homogenate was
split in two aliquots, one was left at room temperature
over night, while the other was immediately frozen and
stored at −80°C until measured. After samples denatur-
ation, following the chosen protocol, the PrP226* was
measured by V5B2/EM20-b ELISA, using 5 μg/ml of
V5B2 (Figure 4A).
Next, we spiked recombinant PrP226* in 10% non-
CJD brain homogenate (without the use of inhibitors) at
concentration 1.5 μg/ml. Aliquots were left at 4°C, at RT
or at 37°C, respectively. From each aliquot samples were
taken at different times (after 30 min, 60 min and
120 min), immediately frozen at −80°C and later loaded
simultaneously to the SDS-PAGE gel. Final loading of
recPrP226* was 5 ng/well. Western blotting of the gel
was performed with V5B2 (5 μg/ml) as detecting anti-
body, as described below (Figure 4B).
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thiocyanate
Two 10% sCJD brain homogenates were mixed with the
same amount of stock solution of denaturant to reach
increasing final concentrations (from 0 M to 3 M) of
guanidine thiocyanate (Gdn-SCN, prepared in 50 mM
Tris, pH 8) and incubated at 60°C for 15 min. Samples
were than 10 times diluted in 50 mM Tris–HCl, pH 8,
and the PrP226* fragment was measured by V5B2/
EM20-b ELISA. The plate was coated with 5 μg/ml of
V5B2.
To test the denaturing effect of Gdn-SCN on coated
antibody, recombinant human PrP226* at 100 μg/ml was
divided into 2 aliquots. The first was treated 1:1 (v/v)
with 3 M Gdn-SCN at 60°C for 15 min, than diluted 5x
and further serially diluted with TBS-T. The second ali-
quot prepared without denaturant was diluted in the
same way.
PrP226* assay
10% brain homogenates were divided into 2 aliquots, the
first was treated 1:1 (v/v) with 3 M Gdn-SCN at 60°C for
15 min. The second aliquot was diluted with the same
amount of 50 mM Tris, pH 8, and kept at RT. Both ali-
quots were further diluted 20x with TBS-T with 1% BSA
(final concentration of the brain homogenate was 0.25%)
and applied to microtiter plates pre-coated with V5B2
(1 μg/ml). PrP226* fragment was detected by biotinylated
EM20 (0.5 μg/ml).
Conformation dependent immunoassays (CDI)
CDI [26] was performed as a sandwich assay according
to Bellon et al. [35], using FH11 (1 μg/ml) as the coating
antibody and biotinylated antibody 3F4 (0.5 μg/ml) as
detecting antibody, followed by the streptavidin-Eu
(PerkinElmer) at concentration 0.125 μg/ml. 10% brain
homogenates were denatured with 8 M Gdn-HCl (1:1 v/v)
and further diluted to a final concentration of 0.25% be-
fore application to the wells. DELFIA was performed as
described above.
Proteinase K digestion of samples
For proteinase K (PK) digestion, brain homogenates
were incubated with 50 μg/ml of PK at 37°C and after
30 min boiled in 5x SDS sample buffer (250 mM Tris,
pH 6.8, 10% SDS and 50% glycerol) for 5 min.
Gel electrophoresis and Western blot analysis
Prepared samples were resolved on 12% SDS polyacryl-
amide gels and proteins on the gels were blotted to
nitrocellulose membranes as described previously [36].
For detection, monoclonal antibodies 6H4 (0.2 μg/ml),
3F4 (0.5 μg/ml) or V5B2 (5 μg/ml) were used. For
Western blots presented in Figure 1, HRP-conjugatedgoat anti-mouse IgG + IgM (JacksonImmunoresearch,
0.2 μg/ml) was used, followed by the ECL detection. For
all other western blots alkaline phosphatase-conjugated
donkey anti-mouse IgG + IgM (JacksonImmunoresearch,
0.2 μg/ml) was used, the reaction was visualized with
BCIP substrate and the signal was quantified densitomet-
rically by MiniLumi gel documentation system utilizing
GelQuant densitometer software (DNR Bio-Imaging
Systems Ltd.).
Immunohistochemistry
For IHC 5 μm thick sections of formalin-fixed and
paraffin-embedded tissue were used. Tissue slices were
deparaffinized and washed in TBS. After that they were
boiled in citrate buffer (pH 7.6) 3x 5 min in a microwave
oven. Endogenous peroxidase was blocked with 0.05 mg
of natrium azide and 5 ml of hydrogen peroxide in
50 ml of distilled water. Non-specific positivity was
blocked with 150 μl of rabbit serum in 10 ml of TBS for
30 min. Before immunostaining, the sections were se-
quentially subjected to PK digestion (10 μg/ml, at 25°C
for 10 min) and guanidine thiocyanate treatment (2 M,
at 25°C for 30 min). The sections were incubated over-
night at 4°C with 6H4 monoclonal antibody (1:2000,
Prionics) diluted in 5% fetal bovine serum in TBS.
Detection of immunostaining was performed using Envi-
sion® kit with DAB chromogen. Specimens incubated
with secondary antibody only and with nonspecific
isotype-matched primary antibodies were used as a con-
trol of specificity. Mayer’s haematoxilin was used as a
nuclear counterstain.
Additional files
Additional file 1: Correlation between the D/N ratio and the
PrP226* quantity in denatured brain homogenates. The data from
this correlation diagram were obtained by V5B2/EM20-b DELFIA. The
values of denatured samples (D) are represented in counts per minute
(cpm). The line represents the slope of linear regression within the 95%
confidence interval.
Additional file 2: Characterization of samples by standard CJD
classifications and by PrP226* assay. Samples are listed by number
together with the result of the sample testing, performed in accordance
with standard CJD classification procedures. An empty space in the table
indicates that the test was not performed. In the last column the average
PrP226* assay results are listed for each sample.
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